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Abstract: Shiga toxin-producing Escherichia coli is a contaminant of food and water that 
in humans causes a diarrheal prodrome followed by more severe disease of the kidneys and 
an array of symptoms of the central nervous system. The systemic disease is a complex 
referred  to  as  diarrhea-associated  hemolytic  uremic  syndrome  (D
+HUS).  D
+HUS  is 
characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal 
failure. This review focuses on the renal aspects of D
+HUS. Current knowledge of this 
renal disease is derived from a combination of human samples, animal models of D
+HUS, 
and interaction of Shiga toxin with isolated renal cell types. Shiga toxin is a multi-subunit 
protein complex that binds to a glycosphingolipid receptor, Gb3, on select eukaryotic cell 
types. Location of Gb3 in the kidney is predictive of the sites of action of Shiga toxin. 
However, the toxin is cytotoxic to some, but not all cell types that express Gb3. It also can 
cause apoptosis or generate an inflammatory response in some cells. Together, this myriad 
of results is responsible for D
+HUS disease. 
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Abbreviations 
TMA—Thrombotic microangiopathic anemia 
D
+HUS—Diarrhea-associated hemolytic uremic syndrome (typical HUS) 
D
-HUS—Non-diarrhea hemolytic uremic syndrome (atypical HUS) 
TTP—Thrombotic thrombocytopenic purpura 
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E. coli—Escherichia coli 
STEC—Shiga toxin-producing E. coli  
EHEC—Enterohemorrhagic E. coli 
VTEC—Verotoxin-producing E. coli 
E. coli O157:H7—The most common type of STEC as a cause of D
+HUS 
Stx—Shiga toxin (a generic term in this paper), same as Verotoxin, previously Shiga-like toxin. 
Stx1—Shiga toxin type 1 
Stx2—Shiga toxin type 2, most common among clinical STEC isolates 
VT—Verotoxin, same as Shiga toxin  
HUVEC—human umbilical vein endothelial cells 
PTC—proximal tubule cells 
IHC—immunohistochemistry 
VEGF—Vascular endothelial growth factor  
TNF—Tumor necrosis factor 
vWf—von Willebrand factor 
MCP-1—Monocyte chemotactic protein type 1 
MIP-2—Monocyte inflammatory protein 
1. Introduction 
This review focuses on the kidney disease caused by Shiga toxin-producing E. coli, referred to as 
diarrhea-associated hemolytic uremic syndrome (D
+HUS). An attempt is made to relate the clinical 
course of D
+HUS in humans with the experimental studies in vitro, and in vivo, i.e., with animal 
models of D
+HUS. Brief descriptions are provided for the structure and function of the Shiga toxins 
(Stx1, Stx2) and its receptor (Gb3). More emphasis has been placed on the interaction of Stx1 and Stx2 
with isolated renal cells and on kidney disease that develops in the animal models. In addition, the role 
of E. coli LPS in D
+HUS is addressed. This review does not include details of how circulating cells 
types are involved in D
+HUS, but rather centers on resident cells of the kidney.  
2. Thrombotic Microangiopathies (TMAs): The Relationship of D
+HUS, D
-HUS and TTP  
The  association  of  E.  coli  Shiga  toxins  with  diarrhea-associated  hemolytic  uremic  syndrome 
(D
+HUS) was established in 1985 [1]. For years, a lack of mechanistic information complicated efforts 
to understand the causes of the other TMAs. Some pertinent reviews of these TMAs are listed [2–11]. 
Fortunately, recent developments in the basic science of the TMAs have provided a causal separation 
for these TMAs. Clinical symptoms of these three diseases are overlapping, and all appear to have 
damaged microvascular endothelium as a primary feature. D
+HUS is caused by the action of Stx on 
multiple  cell  types  in  the  kidney  whereas  D
-HUS  (atypical  HUS)  is  caused  by  dysfunctional 
complement regulatory proteins, and TTP is initiated by deficient ADAMTS13 protease activity for 
degradation of platelet-activating ultra large von Willebrand factor (vWf) multimers.  
Despite the distinct initial causes of each, there are hints of biological mechanisms that may overlap 
in the disease processes. For example, it is not entirely clear if altered complement activity, a key 
feature of D
-HUS, or abnormal von Willebrand factor in TTP also have a role in predisposing some Toxins 2010, 2                         
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individuals to the action of Shiga toxin in D
+HUS (typical HUS) [12,13]. This also opens the door for 
the  potential  role  of  genetic  predisposition  for  D
+HUS.  Such  genetic  predisposition  exists  for 
complement regulatory factor proteins in D
-HUS and for ADAMTS13 protein, a von Willebrand factor 
cleaving protease in TTP [5,14–17]. It is important to note that the need remains to determine the 
specific  cause  of  each  of  the  individual  hallmarks  of  TMA;  thrombocytopenia,  microangiopathic 
hemolytic anemia, and acute renal failure.  
Another very important component of these diseases is the neurological sequelae. The causes of the 
changes in CNS function are the least studied among of the TMAs. Although the endothelium remains 
a focal point here as it does for the corresponding renal disease, new findings in D+HUS indicate the 
neuron is a plausible target for Shiga toxin in the CNS [18–21]. 
In this review, the animal models discussed are referred to a D
+HUS models, although some of these 
do not include a diarrheal phase. However, they all result in renal disease related to Shiga toxin action 
and exhibit aspects of D
+HUS in humans. 
3. Time Course Development of D+HUS  
An accurate timeline for D
+HUS was derived from a large prospective clinical patient referral study 
of children in the Pacific Northwest [22]. Three days after ingesting STEC-contaminated material, 
individuals develop moderate diarrhea and significant abdominal pain. Approximately 3 days later, 
bloody diarrhea develops in most of these individuals prompting medical attention. It is here that a 
stool sample is taken for analysis of STEC and Shiga toxin. Importantly, it is during the hemorrhagic 
colitis stage that Stx1 and/or Stx2 enter the blood circulation setting in action a series of toxemic 
reactions that culminate in renal failure in 5–15% of the patients. STEC does not colonize the blood, 
thus D
+HUS is a toxemic rather than a bacteremic event. The toxemic period advances to acute renal 
failure in approximately 4 days after the hemorrhagic colitis phase. Fortunately, most patients resolve 
the systemic complications and do not progress to renal failure. Although the latter 4 days represent a 
potential ‘therapeutic window’, there is no therapeutic treatment other than fluid volume control and 
dialysis currently available to reduce or prevent renal failure in D
+HUS. Another complicating factor in 
D
+HUS is that antibiotics are not recommended in the earlier phases, i.e., prior to appearance of bloody 
diarrhea  because  STEC  bacteria  respond  to  some  antibiotics  by  producing  excess  Shiga  
toxin [23,24]. The topic of therapeutics is briefly addressed in a section below for identification of 
therapeutic targets to prevent renal damage.  
4. Shiga Toxin-Producing E. coli (STEC)  
This form of Escherichia coli (E. coli) bacteria is a pathogen associated with contamination of  
food  and  water.  Equivalent  terms  for  this  E.  coli  are  Shiga  toxin-producing  E.  coli  (STEC),  or  
Verotoxin-producing  E.  coli  (VTEC).  The  primary  virulence  factor  in  systemic  host  responses 
produced by clinical isolates of STEC is Shiga toxin type 2 (Stx2), but some isolates produce both Stx1 
and Stx2, or more rarely only Stx1 [25–27]. Numerous other factors produced by STEC are believed to 
act locally in the intestine rather than systemically as do the Shiga toxins. The reservoir for STEC is 
primarily  bovine,  however  other  domestic  and  wild  animals  with  rumen  digestive  systems  are  all 
capable of harboring STEC [28,29]. It appears that Stx does not cause disease in these animals due, in Toxins 2010, 2                         
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part, to a paucity of functional Stx receptor in the animals [30]. STEC is an efficient pathogen in 
humans as ingestion of less than 100 bacteria is sufficient to colonize the colon. Thus, ground beef, 
water,  or  vegetables  contaminated  with  bovine  feces  are  a  risk  to  the  public  as  are contaminated 
unpasteurized milk or apple cider. The most common form of STEC is E. coli O157:H7, although there 
are other E. coli serotypes that produce Stx1 and/or Stx2 which cause D
+HUS [31,32].  
5. Shiga Toxin Structure and Function  
It is commonly accepted that Shiga toxin (Stx) is the primary virulence factor of pathogenic STEC 
bacteria in D
+HUS [1,33,34]. Evidence for the total dependence on Stx for the vascular effects of 
disease was provided in a lower primate model [35]. In this study, a comparison was made in host 
responses  following  oral  inoculation  with  wild  type  Stx-producing  pathogenic  bacteria  vs.  with  a  
Stx-deficient  strain  of  the  pathogen.  The  intestinal  hemorrhagic  response  was  observed  only  with  
the wild-type bacteria. The following is an abbreviated description of structure and functions of the 
Shiga toxins.  
5.1. Structure of Shiga Toxin  
All of the Shiga toxins comprise a single 30 kDa A-subunit and a pentamer of non-covalently 
attached identical 7 kDa B-subunits [36]. Enzymatic activity resides in the A-subunit whereas the cell 
recognition receptor binding properties are in the B-subunits. The Stx receptor, Gb3, is described in 
more detail in the following section. The genes for Shiga toxin are located on a bacteriophage (a virus 
of  bacteria)  that  is  associated  with  all  pathogenic  STEC.  The  toxin  gene  is  transcribed  and  its 
messenger RNA translated with subsequent assembly of the holotoxin for export to the periplasmic 
space in the bacteria or secreted by the bacteria.  
5.2. Stx1 vs. Stx2  
Despite related primary amino acid sequences, Stx1 and Stx2 are immunologically distinct [33]. In 
addition, Stx1 and Stx2 do not target exactly the same tissues and organs although both bind Gb3 and 
are capable of causing D
+HUS [37–39]. These properties are realized in animal models of disease 
where Stx2 is many times more potent than Stx1 in mice with the reverse being true in rabbits [40]. 
However, Stx2 is most commonly associated with clinical isolates of STEC and thus is believed to be 
the primary form of importance in human disease.  
Unfortunately, there is no universal source of highly purified toxin available to all researchers that 
would eliminate the variability in experiments from different laboratories. Some commercial sources of 
these  toxins  are  only  50%  pure,  yet  results  from  experiments  performed  with  such  toxin  are 
occasionally reported to be due to the toxin itself. This remains a problem and is one that actually 
provides a valid explanation for some disparate results among related experiments. LPS is a much 
more potent pro-inflammatory agent than Stx and results due to LPS vs. Stx is valuable knowledge for 
an understanding of D
+HUS. Thus, it is important that Stx1 and Stx2 preparations be processed to 
remove contaminant proteins and residual LPS, and prior to use the final toxin preparation should be 
analyzed by silver staining following gel electrophoresis, by dose-response in a Vero cell cytotoxicity Toxins 2010, 2                         
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assay, and by neutralization of biological activity with toxin-specific monoclonal antibodies in the 
Vero cell assay. Interpretation of data should also take into account the amount of Stx employed in 
animal experiments. In some cases, there has been a 10 to 40-fold difference in the amount of Stx2 that 
has been used for murine experiments. The data derived from studies using 10 or 20-times the lethal 
dose of toxin is likely to be less useful for interpretation purposes.  
5.3. Shiga Toxin Internalization Processing, Enzymatic Activity, and Cellular Responses  
Following binding to Gb3 on target eukaryotic cells, the Stx-receptor complex is internalized and 
locates  within  endosomes.  Rather  than  moving  to  lysosomes  for  degradation,  the  complex  is 
transported in a retrograde manner through the golgi to the endoplasmic reticulum (ER) [41]. It is here 
that  the  Stx  A-subunit  is  cleaved  by  a  furin-like  protease,  releasing  the  enzymatically  active  
A1-subunit  into the cytoplasm  where it exerts its effect on ribosomes  [42]. Alternatively, there is 
evidence that internalized Stx-Gb3 can be transported directly to nuclei [43,44]. However, in the latter 
case, the action of Stx in the nucleus has yet to be delineated.  
The Shiga toxins enzymatically inactivate the eukaryotic ribosome by removal of a single adenine 
base from 28S rRNA within the large (60S) ribosomal subunit [45]. This is an irreversible process that 
renders the ribosome defective for interaction with eukaryotic peptide elongation factor for binding of 
aminoacyl-tRNA and elongation of nascent peptide [46].  
Shiga toxin can exert its effects on eukaryotic cells by one of three known mechanisms. Firstly, 
inactivation of ribosomes and inhibition of cytoplasmic protein synthesis can result in cell death [47]. 
Secondly, Shiga toxin-dependent generation of the depurinated 28S rRNA in ribosomes initiates a 
unique  signal-transduction  response  known  as  the  ‘ribotoxic  stress  response’  (RSR)  that  leads  to 
activation of cytokines, chemokines, or other factors that result in numerous different events including 
apoptosis  of  the  affected  cell  [48].  The  signaling  pathways  activated  in  the  RSR  include  the  
mitogen-activated protein kinases (MAPK) such as p38MAPK [48–51]. Interestingly, these activities 
appear to be due to other than inhibition of protein synthesis. Thirdly, receptor binding of Stx holotoxin 
or its B-subunit alone can initiate a cytoplasmic signal-transduction cascade different from the RSR 
response-activated  pathway  [52,53].  This  process  requires  one  or  more  factors,  likely  membrane 
proteins with a cytoplasmic domain because Gb3 itself is incapable of initiating cytoplasmic signaling. 
Recently, candidates for the ‘unknown’ factor have been suggested [52,54–56]. 
Thus, Stx can exert different responses in a cell type-specific manner. The end results of these 
events can be cell death (apoptosis, necrosis) or inflammatory responses in cells that remain viable, and 
perhaps other intermediate responses. 
6. Shiga Toxin Receptor, Globotriaosyl Ceramide (Gb3)  
The Stx receptor is a major determinant and of central importance to D
+HUS kidney disease [57–60]. 
The receptor for Stx1 and Stx2 is a neutral glycosphingolipid, globotriaosylceramide, abbreviated Gb3. 
Gb3 is synthesized in golgi of select eukaryotic cells and transported to the plasma membrane where it 
resides in the outer leaflet with its trisaccharide moiety facing outward and the hydrocarbon ceramide 
(C-16 to C-24) moiety non-covalently arranged within the plasma membrane. The binding subunit of 
Stx specifically recognizes the terminal alpha-1,4 di-galactose of the trisaccharide. A molecule of Stx Toxins 2010, 2                         
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contains five binding (B-) subunits, each capable of binding one or more molecules of Gb3, resulting in 
cooperative high affinity binding of Stx to cells with a Kd of approximately 0.1 nM [61,62]. The 
importance of Gb3 in Stx action is evident from cell culture and animal studies where the absence of 
Gb3 eliminates the response to Stx [63,64]. 
There is a relationship between the amount of Gb3 in cells and their sensitivity to Stx, although this 
appears not to be stoichiometric. Other receptor-related determinants of Stx sensitivity of a cell are 
complex biochemical aspects of the Gb3 membrane microenvironment. In brief, much or perhaps most 
of the Gb3 in a plasma membrane may not be reactive with Stx. This cryptic Gb3 may be a function of 
direct interaction of the Gb3 ceramide moiety with other membrane components including cholesterol, 
other  glycolipids,  fatty  acids,  or  proteins  [65–68].  This  concept  helps  explain  why  a  tissue  often 
appears to bind much less Stx compared to the total amount of Gb3 that is extractable from the tissue. 
The story of Gb3 and plasma membrane microdomains is only now coming into focus [67,69–72]. 
Thus,  Gb3  molecules  with  identical  trisaccharides,  but  different  ceramides,  may  be  arranged  in 
membranes differently leading to their differential interaction with Stx1 vs. Stx2. It is more difficult to 
accept that two molecules of Gb3, identical in all respects, may have differential preference for the 
toxins. However, as described above, different domains of plasma membranes being unique appear to 
influence the presentation of identical Gb3 molecules and reactivity with Stx1 or Stx2. 
What this means for D
+HUS kidney disease is that it remains important not only to determine where 
and how much Gb3 is localized to different renal cell types, but also if the Gb3 is reactive with Stx1 or 
Stx2. Finally, the host response to Stx should represent a change in physiology consistent with the 
known function of the cell type.  
7. Shiga Toxin Receptor Localization in the Kidney  
Differential expression of Stx receptor (Gb3) by cell types of human and animal kidney is a reliable 
predictor of Stx site of action. Gb3 has been detected in homogenates of total kidney from human and 
animals. In these cases, detection methodologies include thin-layer chromatography with detection of 
Gb3 by Stx overlay, high-performance liquid chromatography, or mass spectrometry of extracted total 
neutral  glycolipids  [73,74].  In  addition,  Gb3  has  been  localized  within  kidney  tissue  samples  by  
anti-Gb3 antibody reactivity or by detection of bound Stx using anti-Stx antibodies [73,75,76]. 
7.1. Stx Receptor Localization in Glomeruli  
Human  glomerular  cell  types  that  express  Stx  receptor  include:  endothelial,  podocyte,  and 
mesangial. It is likely that these cell types in baboon glomeruli also express the Stx receptor. Porcine 
glomerular endothelial cells are positive for Gb3 [77–79]. Glomeruli from Dutch belted rabbits, but not 
from New Zealand White rabbits appear to develop lesions following oral infection with STEC [80–83]. 
Murine, and perhaps all rodent glomerular cells do not express Stx receptor [12,39,84].  
7.2. Stx Receptor Localization in Extra-Glomerular Regions  
In humans, and most animal models of D
+HUS, Gb3 is expressed by proximal tubules [39,85–87]. 
Porcine and murine renal  tubules  express Stx receptor and bind Stxs  [78,79]. Human and murine Toxins 2010, 2                         
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collecting duct cells also express Gb3 [84]. A systematic study of in situ Gb3 localization in other 
epithelial cells of the nephron in human or animal kidneys has not been completed as this requires 
demonstration of co-localization of Gb3 with markers specific for each cell type along the nephron.  
It has been reported that in murine kidneys, Gb3 co-localizes with aquaporin-2, a marker of collecting 
duct cells [84]. Unexpectedly, murine collecting ducts express more Gb3 than do proximal tubules.  
8. Animal Models of D
+HUS  
8.1. General Comments  
It is not the purpose of this review to provide details of animal models of D+HUS [88]. Animal 
models of D
+HUS have been employed for the salient reason that human studies are limited to analysis 
of  blood  and  urine  samples,  a  rare  renal  biopsy  or  autopsy  sample.  Prior  to  animal  models,  the 
discussions of mechanisms of D
+HUS were based largely on the analysis of human renal tissue autopsy 
samples. However, autopsy samples represent late stage changes which are inherently less helpful for 
determining the mechanisms of pathogenesis. The ideal animal model of D
+HUS would start with oral 
inoculation of fully virulent STEC and end with complete D
+HUS. For a number of reasons, this ideal 
model does not exist. Nonetheless, much valuable information has been obtained from animal models 
of D
+HUS that begin with either oral inoculation of the pathogen or with direct intraperitoneal or 
intravascular injection of the purified toxin.  
The most common animals utilized in D
+HUS studies are the mouse, rabbit, pig, and baboon. The 
following are some generalities generated from the D+HUS animal studies of many different groups. 
Firstly, each animal model is distinct and different in response to either STEC bacteria or purified Stx1 
or Stx2. Secondly, the animal models differ in location of the organ damage (i.e., kidney, intestine, 
CNS) which most closely represents that of human D
+HUS. Thirdly, the mouse has been the most 
utilized D
+HUS model for baseline knowledge, cost, availability of reagents, and genetic applications 
[40,89–95]. Fourthly, the baboon D
+HUS model most closely represents D
+HUS of humans and for 
this reason will continue to be important for validation of data derived from the small animal models of 
D
+HUS [96–100].  
8.2. Mouse  
Results  from  the  mouse  model  of  D
+HUS  have  been  instructive  for  kidney  disease  whether 
beginning  from  oral  STEC  or  injected  (i.p.  or  i.v.)  Stx1  and  Stx2  [39,76,90,92,93,95,101–104].  
A mouse-specific strain of STEC exists, but has yet to be studied in detail in mice for renal disease, 
although  the  pathogen-free  mouse  inoculated  with  STEC  has  yielded  information  of  renal  
disease [93,94]. The mouse D
+HUS model also has been useful for application of host gene-arrays in 
analysis of renal responses, something that is not yet available for rabbit, pigs, or baboons [92]. The 
primary disadvantage of the mouse model of D
+HUS is that mice, and perhaps all rodents, do not 
express Stx receptor on their endothelium [12,84]. It appears that some vascular changes in the murine 
D+HUS model require the combined action of Stx2 and LPS [92,105,106]. The renal coagulation and 
thrombosis  observed in  the Stx2/LPS mouse model is  driven by LPS induction  of chemokines  in Toxins 2010, 2                         
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proximal  tubule  cells  with  Stx2  prolonging  the  half-life  of  the  chemokine  mRNAs  [92,105]. 
Neutralization of the chemokines with monoclonal antibodies inhibited this coagulation and thrombosis.  
8.3. Rabbit  
The Dutch Belted rabbit develops acute renal failure following exposure to STEC, but exhibits a 
low  and  variable  rate  of  response  [80–82].  A  naturally  existing  rabbit-specific  variant  of  STEC 
discovered  in  Dutch-belted  rabbits  remains  a  source  of  inoculum  for  renal  disease  studies  and  is 
adaptable to other types of rabbits [80].  
8.4. Pig  
The pig model of Stx-induced renal disease has not been described in detail, but it demonstrates 
tubular damage [79,107–109]. A natural STEC that produces Stx2e is associated with systemic disease 
in piglets [110].  
8.5. Baboon  
Finally, the baboon appears to be the ‘acid test’ model of D
+HUS for kidney failure because the 
physiology most closely represents that of the human kidney [96–100,111]. The primary disadvantages 
of  the  baboon  for  this  purpose  are  its  difficult  use  for  oral  inoculation  studies  and  lack  of  
species-specific gene microarrays. Results  of STEC or Stx related kidney damage in these animal 
models are discussed in more detail below.  
9. The Kidney as a Target of Shiga Toxin 
9.1. Why the Kidney?  
It is not totally clear why the kidney, aside from the CNS, is the most affected organ in D
+HUS. 
Although Stx from the intestine would traverse the lung prior to encountering the kidneys, damage to 
the lungs in D
+HUS is secondary in severity to that of the kidneys. A plausible explanation is the 
kidney expresses the most abundant amount of biologically active Stx receptor and thus contains the 
most Stx-sensitive cell types. Another reason is the high volume of blood flow and filtration rate of 
blood in kidneys increase the chance of Stx interaction with cells of the renal microvasculature and the 
filtration barrier. Indeed, as described in more detail below, human renal endothelial and podocyte cells 
are very sensitive to the action of Stx2 [84]. In addition, should the renal filtration barrier become 
damaged, Stx would have an opportunity to interact with the different tubular epithelial cells types 
which comprise the nephron. Again, there is evidence that some of these latter cell types do express 
sufficient Stx receptor to be candidates for Stx-induced disease. 
9.2. Differential Sites of Action for Stx1 vs. Stx2.  
Injection of animals with Stx1 or Stx2 results in preferential damage to organs including kidney and 
lung. Stx1 appears to target the lung while Stx2 prefers the kidney [39]. A data-based explanation for 
this phenomenon is beginning to come forward as more is revealed about the biological relationship of Toxins 2010, 2                         
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Gb3 with plasma membranes [65–67,71,112,113]. A complete study of the differential effects of Stx1 
vs. Stx2 on kidney has not been performed in animal models of D+HUS.  
10. Renal Cell Types Sensitive to Stx 
10.1. General Comments  
An ongoing process in studies of D
+HUS is to digest the large volume of data derived from human 
renal cells in vitro, and to connect these data in a meaningful way with information about renal damage 
in  humans.  A  recent  review  describes  the  use  of  different  renal  cell  types  in  the  study  of  renal  
disease  [114].  There  is  good  reason  to  believe  that  certain  human  renal  cell  types  would  be  an 
important part of the D
+HUS disease process should they express Gb3, be sensitive to Stx in vitro, and 
are located within a part of the kidney identified with the pathological disease in D
+HUS. To date, 
these include human podocyte, endothelial, mesangial, proximal tubule and collecting duct tubule cells. 
These are discussed in more detail below.  
10.2. Renal Endothelial Cells  
If there is any consensus among clinicians and researchers in the field of D
+HUS, it is that the 
endothelium is a likely target of Stx [115]. Examination of renal pathological samples typically reveals 
swollen and detached glomerular endothelium. The complementary data supporting the concept that 
endothelial cells represent a primary target in D
+HUS was provided in a Stx1 cytotoxicity assay with 
human umbilical vein endothelial cells, HUVEC [47,116]. In these studies, a series of primary cell 
isolates were prepared from individual umbilical cords. Although most cell isolates were relatively 
resistant  to  Stx  (LD50  =  1nM  Stx),  it  was  noted  that  approximately  7%  of  the  isolates  were  10  
to 100-times more sensitive to concentrations of Stx1 [117]. This was a stable phenotypic property of 
the HUVECs. Although large vessel endothelium is not damaged in D
+HUS, this observation could 
possibly be related in terms of genetic predisposition to the similar percentage of individuals who 
progress to renal failure in D
+HUS. Subsequent studies showed that most HUVEC express little Gb3 
compared  to  human  microvascular  renal  endothelial  cells,  thus  providing  an  explanation  of  the 
generally poor sensitivity of large vessel vs. microvascular endothelial cells [118,119]. A conceptual 
disconnect remains in that human renal microvascular cells (HRMEC) are exquisitely sensitive to the 
lethal effects of Stx in vitro, but in vivo HRMEC only become swollen and detached from the basement 
matrix in D
+HUS. This suggests the presence of a mechanism that partially protects renal endothelium 
from  Stx  in  vivo  that  does  not  exist  in  vitro.  The  biological  cross-talk  between  the  glomerular 
fenestrated endothelium and podocytes may be important to this phenomenon [120]. As with other 
different diseases of the kidney, damage to individual glomeruli is less than uniform or complete in 
D
+HUS. 
Animal models of D
+HUS differ in their response of glomerular endothelium to the direct action of 
Stx. Importantly, baboon, rabbit and pig express Stx receptor on their microvascular endothelial cells 
while mice do not [77,84,96,98,121]. Thus, in the mouse models of D
+HUS, all of the changes in 
biology and pathology of renal endothelium related to Stx must be indirect. Some insight into how this 
might occur is provided below, particularly for the observed coagulation and thrombosis [92,93,105]. Toxins 2010, 2                         
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Given  these  differences  for  the  renal  endothelium  among  animals,  it  is  not  surprising  that  
some  animal  models  of  D
+HUS  are  associated  with  more  complete  occlusion  of  glomerular 
microcapillaries [12,83,92,93,96,99,122–126]. 
The glomerular endothelium, being part of the filtration barrier of the kidney, when damaged can 
become leaky and may, in part, be responsible for proteinuria and appearance in the urine of host 
cytokines,  chemokines,  and  other  biological  markers  of  disease.  However,  some  inflammatory 
mediators appear to be of renal origin in D+HUS.  
10.3. Podocytes  
Human podocytes (visceral epithelial cells) are almost as sensitive to Stx2, in vitro, as are human 
renal microvascular endothelial cells and they also express an ample amount of Stx receptor [84]. 
Analysis  of  human  D
+HUS  pediatric  kidney  on  autopsy  revealed  Stx  binding  to  podocytes  [127].  
As with endothelial cells, mouse podocytes also do not express the Stx receptor and are insensitive to 
Stx2  [84].  However,  the  Stx-sensitivity  status  of  podocytes  in  other  animals  is  not  as  clear.  The 
primary role of podocytes includes participation in the blood filtration barrier along with glomerular 
endothelium  and  basement  membrane  [128,129].  Podocytes  also  provide  VEGF  in  support  of 
glomerular endothelium [120,130–132] and utilize VEGF beneficially in an autocrine manner [133]. 
Alteration of podocytes is a feature of several well-known renal diseases including focal segmental 
glomerular sclerosis (FSGS), polycystic kidney disease (PKD), diabetic nephropathy (DN) [134–136]. 
Damaged podocytes have also been suggested as a key component of preeclampsia which shares some 
clinical  features  with  D
+HUS  [137,138].  Stx  was  reported  to  increase  endothelin-1  in  human  
podocytes [139]. Additional studies are needed to determine the relative importance of podocytes as a 
target of Stx in D
+HUS. However, biomarkers of podocyte damage have been detected in urine of 
D
+HUS  patients  [140,141].  Importantly,  Stx2  decreases  VEGF  production  by  human  podocytes,  
in vitro [84].  
10.4. Mesangial Cells  
It is often reported that the pathology of human D
+HUS kidney includes mesangial expansion or 
proliferation [142–144]. These glomerular cells bind and internalize Stx in vitro, with reported changes 
in mesangial physiology, but the relative role of mesangium in Stx-induced glomerular disease is less 
studied than for other renal cell types [127,143,145–147]. Animal D
+HUS model studies have reported 
changes in the rabbit mesangium, but not in the murine or baboon models [81,92,93,96].  
10.5. Proximal Tubular Cells (PTC)  
Many reports place proximal tubular cells at the top of the list along with endothelial cells for renal 
cell types that respond to Stx and are of importance in D
+HUS. Due to the availability of primary and 
immortalized cell lines, human PTCs are the most studied in D
+HUS. Gb3 has been localized to PTCs 
from human and animal kidneys [39,86,148]. Responses of PTCs to Stx1 and Stx2 include inhibition 
of  protein  synthesis,  induction  of  cytokines  [86,148],  chemokines  [105],  and  tissue  factor  [87], 
apoptosis [149], necrosis [85,86,95,101,150], and inhibition of water reabsorption [151]. The normal Toxins 2010, 2                         
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function of proximal tubule cells is to reabsorb urinary solvents and solutes which pass through the 
glomerular filtration barrier so as to maintain proper volume and solute concentrations in the blood 
circulation [152]. A complicating factor is that inflammation and related signaling pathways become 
activated in podocytes exposed to excess protein [153–155]. 
10.6. Collecting Duct Cells  
Collecting duct cells in human kidneys were reported to express Gb3 [75]. In murine kidney, these 
cells express ample Gb3 that co-localizes in the plasma membrane with aquaporin 2, a specific marker 
of collecting duct cells, and respond to Stx2 in an apoptotic manner [84]. This also has implications for 
the renal features of D
+HUS as the collecting duct cell functions to maintain water balance of the body. 
In  D
+HUS  patients  (and  most  animal  models),  dehydration  is  a  prominent  feature,  presenting  as 
oliguria  and  anuria  which  must  be  treated.  Initial  data  suggest  that  prevention  of  Stx2-dependent 
damage to these cells helps preserve renal function in the murine model of D
+HUS [84].  
11. Why is the Incidence of D+HUS More Common in Children?  
Most  D
+HUS  is  associated  with  young  children  although  individuals  of  all  ages  can  develop 
D
+HUS. A simple explanation would be that more Gb3 is expressed in the kidneys of the young. 
However, this has proven not to be the case as there is more Gb3 extractable from kidneys of adults vs. 
children [60,75]. An alternative explanation is that pediatric kidney expresses more Gb3 on cells that 
are more involved in biological responses leading to D
+HUS. It is interesting that only pediatric kidney 
expressed  Gb3  in  glomeruli  [75].  An  independent  verification  of  these  data  would  be  helpful. 
Information is only now becoming available in support of another concept, that the plasma membrane 
microenvironment  nearby  Gb3  dictates  the  biological  response  to  Stx  [65–68,70,156,157].  Such 
conjecture  can  be  carried  further  to  include  other  variables  such  as  differential  trafficking  of  the  
Stx-Gb3 complex inside target cells and/or activation of signal transduction pathways that are more 
damaging  to  the  target  cell.  Although  reports  on  these  sub-topics  are  needed,  methodologies  are 
currently available to sufficiently provide answers to these problems. Others have reported that an 
‘immunological  memory  response’  may  be  responsible  for  the  higher  incidence  of  D
+HUS  in  
children [158,159]. It is reasonable that more than one of these mechanisms may be functional in 
pediatric D
+HUS. 
12. Is There a Role for E. coli Lipopolysaccharide (LPS) in D+HUS?  
Humans with D
+HUS develop circulating antibodies to STEC LPS [160–162]. Thus, the blood may 
serve as a delivery system not only for Stx, but for LPS as well. Importantly, LPS is a much more 
potent pro-inflammatory agent than either Stx1 or Stx2. For example, LPS caused significant changes 
in the activities of many more genes of the murine kidney than did Stx2 [84]. Due to the ubiquitous 
distribution of LPS receptor (TLR4) in most host tissues and in cells along the nephron, there is ample 
reason  to  believe  that  LPS  from  STEC  may  be  involved  in  some  aspects  of  D
+HUS  [163].  This 
becomes more apparent considering documented direct interaction of LPS with the kidney [164–168]. 
However, quantitative data regarding LPS in the blood of D
+HUS patients is needed. In the murine Toxins 2010, 2                         
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model of D+HUS, one of the three hallmarks of D
+HUS was driven by LPS rather than be Stx2 [92]. In 
addition, some human renal cell types respond directly to LPS [163,169–176]. It is clear that activation 
of platelets in D
+HUS requires initial interaction with LPS [177–179]. Murine and human glomerular 
endothelial and podocyte cells respond to LPS [84]. Some actions of LPS in vitro are not restricted to 
LPS from STEC, but appear to require the lipid A moiety (endotoxin) common to all E. coli LPS [180]. 
There  is  evidence  that  LPS  enhances  the  actions  of  Stx  in  animal  models  of  
D
+HUS  [89,106,174,177,179–188].  LPS  has  been  associated  with  induction  of  Gb3  in  human 
endothelial cells in vitro [180], and in baboon renal glomerular endothelial cells, in vivo [111]. In the 
murine model of D
+HUS, a study of temporal renal responses demonstrated early (0–24 h) changes 
were due to LPS and later (24–96 h) changes were due to Stx2 [92]. In addition, these gene microarray 
data showed the renal responses to LPS and Stx2 appeared to be additive rather than synergistic. More 
studies are needed to further define the specific responses to LPS vs. Stx2 throughout the kidney and to 
determine the level of circulating LPS in D
+HUS patients.  
13. The Role of Circulating Cell Types in Renal Disease of D+HUS 
General Comments 
Several cell types in the blood circulation have been implicated in different aspects of D
+HUS. The 
more  prominent  aspects  of  this  sub-topic  are  the  following.  Although  controversial,  circulating 
neutrophils have been implicated in binding and trafficking of Stx in humans and animals [189–193]. 
Data  exist  supporting  or  refuting  an  essential  role  of  neutrophils  and/or  monocytes  in  D
+HUS. 
Monocytes and macrophages may be a source of cytokines and chemokines in D+HUS [105,194–198]. 
Finally, platelets certainly play a central role in D
+HUS not only because thrombocytopenia is one of 
the  hallmarks  of  the  disease,  but  for  their  active  role  as  inflammatory  mediators  [177–179]. 
Conversely,  some  chemokines  elicited  by  Stx  in  endothelial  or  monocytic  cells  can  serve  as  
co-activators of platelets [106,184,199].  
14. Conclusions 
Renal aspects of D
+HUS are complex due to the numerous variables in primary, secondary, etc., 
targets of Stx and the timing of responses to both Stx and LPS. We now know considerably more about 
the biochemical mode of action of Stx than we do about the disease process it causes. However, much 
has been learned about the role of Shiga toxin and LPS in the renal physiology and disease in D
+HUS. 
Most  of  the  renal  cell  types  involved  in  the  disease  have  been  identified  and  their  respective 
contributions  are being revealed.  Strides have been made in  equating the animal model data with 
D+HUS of humans. An active movement is on to determine the relative importance in D+HUS of 
factors  known  to  function  in  D
-HUS  and  TTP,  such  as  complement  regulatory  proteins  and  vWf 
proteases. Finally, the field has advanced sufficiently so as to identify therapeutic targets in D
+HUS 
with the hope of impeding or preventing renal failure itself. Toxins 2010, 2                         
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